DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Intravenous Immunoglobulins for Post-Polio Syndrome

Information source: Azienda Ospedaliera Universitaria Integrata Verona
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Post-polio Syndrome

Intervention: intravenous immunoglobulins (Biological); Saline solution (Biological)

Phase: Phase 3

Status: Completed

Sponsored by: Azienda Ospedaliera Universitaria Integrata Verona


Postpolio syndrome is a condition that affects many polio survivors years after the acute infection and causes symptoms to increase or new symptoms to develop. Proinflammatory cytokine production within the central nervous system (CNS) indicates an underlying inflammatory process, amenable to immunomodulatory therapy. In this study the investigators sought to confirm that antiinflammatory treatment with intravenous immunoglobulin improves the disease.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: SF-36 physical component


Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- a history of acute poliomyelitis

- increased muscle weakness, muscle fatigue and pain in muscle groups previously

affected by poliomyelitis

- a diagnosis of postpolio syndrome according to the criteria of Halstead and Rossi

Exclusion Criteria:

- clinically relevant systemic disease

- malignancy

- hypothyroidism

- diabetes mellitus not fully controlled by medical therapy

- medical or orthopedic disorders that could give rise to symptoms mimicking post-polio


- conditions associated with prolonged coagulation time

- serum IgA deficiency

- previous allergic reaction to IVIG

- body-mass index greater than 30

- immune-modulating treatments other than IVIG within the preceding 6 months

Locations and Contacts

Additional Information

Starting date: January 2008
Last updated: February 23, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017